Mutations in IDH1 and IDH2 have been reported in approximately 20% of de novo AML [17,18,19,20,21], and their presence is an unfavorable prognostic factor according to most studies [22,23,24,25,26]. Here, IDH2 is linked to acute myeloid leukemia.